ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
Financial & Business 
Read more
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
Science & Medicine 
Read more
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
Science & Medicine 
Read more

Gamma Delta T Therapies Summit

From  Jul 26, 2022  to  Jul 28, 2022 

Read more

Festival of Biologics

From  Nov 02, 2022  to  Nov 04, 2022 

Read more

PEGS Europe

From  Nov 14, 2022  to  Nov 16, 2022 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news